**INVICTA DIAGNOSTIC LIMITED**
CIN: L86100MH2023PLC414723
**Registered Office:** 1 Ground Floor, Plot No. 217, Ambavat Bhavan, N.M Joshi Marg, Delisle Road, Mumbai – 400 013. | Email: info@pcdiagnostics.in | Contact: 022 4971 0036

**November 14th, 2026**

**National Stock Exchange of India Limited**
Exchange Plaza, 5th Floor, C-1,
Block G, Bandra Kurla Complex,
Bandra (E), Mumbai 400051

**NSE SYMBOL: INVICTA**
**ISIN: INE0XJ501010**

**Subject: Outcome of Board Meeting held today i.e. Saturday, November 14th, 2026 in terms of Regulation 30 and 33 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015**

**Dear Sir/Madam,**

In reference to the captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held today, i.e. Saturday, November 14th, 2026, which was commenced at 6.00 PM and concluded at 8.15 PM:

1. Upon the recommendation of Audit Committee, has considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the Half Year ended September 30, 2026 ("Financial Results"). A copy of financial results along with Limited Review Report is enclosed herewith;

   Further pursuant to SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 read with relevant circulars issued by stock exchanges in this regard, the following disclosures are being made:

   A. Financial Results – **enclosed**
   B. Statement on deviation or variation for proceeds of Public Issue, Rights issue, Preferential Issue, Qualified Institutional Placement etc. – **Annexure 1**
   C. Format for Disclosing Outstanding Default on loans and Debt Securities - **Not Applicable**
   D. Format for disclosure of Related Party Transactions – **Annexure II.**
   E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted along with annual audited financial results (Standalone and Consolidated separately) (applicable for only Annual Filing i.e. 4th quarter) - **Not applicable.**

2. The Board decided to defer the proposal for acquisition of existing diagnostic centre businesses in Nashik through a subsidiary of the Company. The said proposal shall be considered at a separate meeting of the Board to be convened for this purpose.

You are requested to take the same on record.

Thanking you,
Yours Faithfully,
**For Invicta Diagnostic Limited**

Sanket Vinod Jain

Digitally signed by Sanket Vinod Jain
Date: 2026.11.14 20:18:48 +05'30'

**Sanket Vinod Jain**
**Chairman and Managing Director**
**DIN: 08299039**
**Place: Mumbai**

KANAK RATHOD & CO.
CHARTERED ACCOUNTANTS

K. B. RATHOD B.COM., F.C.A.

Flat No. 203, New Swapnalok C.H.S. Ltd.,
Natakwala Lane, S.V. Rd., Borivali (West),
Mumbai : 400 092.
Mob: 9869243109.
E-mail: cakanak51@gmail.com

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (as amended).**

**Review report**

To,
The Board of Directors of
Invicta Diagnostic Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Invicta Diagnostic Limited ('the Company') for the half year ended September 30, 2026 together with notes thereon (the "Statement"), being submitted by the Company pursuant to the requirements of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (as amended) (Listing Regulations').

2. This statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25, Interim Financial Reporting ("AS 25"), prescribed under section 133 of the Companies Act 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of making inquiries, primarily of person responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143 (10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in

KANAK RATHOD & CO. M. No. 32633 MUMBAI CHARTERED ACCOUNTANTS

an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed or that it contains any material misstatement.

**For Kanak Rathod & Co.**
**Chartered Accountants**
**Firm Regn No: 104700W**

K.R. Rathod

KANAK RATHOD & CO. M. No. 32833 MUMBAI CHARTERED ACCOUNTANTS

**Kanak Rathod**
**Proprietor**
**Membership No: 032833**
**Date: 14/11/2026**
**Mumbai**
**UDIN:** 26032833DQKINT6747

## Invicta Diagnostic Limited

(CIN: L86100MH2023PLC414723)

Reg. Off.:1 GF, Plot 217, Ambavat, Bhavan, N.M Joshi Marg, Delisle Road, Mumbai, Mumbai, Maharashtra, India, 400013

Corp. Off.: 1012 10th Floor Hubtown Viva CHS LTD Western Express Highway, Mogra Village Near Shankar Wadi Jogeshwari East, Jogeshwari East, Mumbai, Jogeshwari East, Maharashtra, India, 400060

Tel: 022-4971 0036 Email-Id: info@pcdiagnostics.in Website: https://www.pcdiagnostics.in/

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED ON 30.09.2026

(Amount in Lakhs)

| SN | Particulars | Half year ended | Preceding Half year ended | Corresponding Half year ended in the previous year | Current Year |
|---|---|---|---|---|---|
| | | 30-Sep-26 | 31-Mar-26 | 30-Sep-25 | 31-Mar-26 |
| | | Unaudited | Audited | Unaudited | Audited |
| 1 | **Income** | | | | |
| | (a)Revenue From Operations | 1379.11 | 965.34 | 1062.32 | 2027.66 |
| | (b)Other Income | 83.10 | 25.30 | 87.95 | 113.25 |
| | **Total Income** | **1,462.21** | **990.64** | **1150.27** | **2,140.91** |
| 2 | **Expenses** | | | | |
| | (a) Cost of materials consumed | 0.00 | 0.00 | 0.00 | 0.00 |
| | (b) Purchase of consumables | 86.01 | 88.10 | 93.20 | 181.30 |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 1.02 | (0.28) | -2.13 | (2.41) |
| | (d) Finance Cost | 3.82 | 2.25 | 1.99 | 4.24 |
| | (e) Employee Benefits Expenses | 203.98 | 171.03 | 122.04 | 293.07 |
| | (f) Depreciation and amortisation expense | 83.53 | 90.57 | 58.00 | 148.57 |
| | (g) Other expenses | 574.64 | 398.66 | 392.07 | 790.73 |
| | **Total Expenses** | **953.01** | **750.33** | **665.17** | **1415.503** |
| 3 | **Profit / (Loss) before exceptional and extraordinary items and tax** | **509.19** | **240.31** | **485.10** | **725.41** |
| | Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 |
| 4 | **Profit / (Loss) before extraordinary items and tax (3-4)** | **509.19** | **240.31** | **485.10** | **725.41** |
| | Extraordinary Items | 0.00 | 0.00 | 0.00 | 0.00 |
| 5 | **Profit/ (Loss) before Tax (5-6)** | **509.19** | **240.31** | **485.10** | **725.41** |
| 6 | **Tax Expenses** | | | | |
| | (a) Current Tax | 116.96 | 45.64 | 100.05 | 145.69 |
| | (b) Deferred Tax | 3.83 | 8.41 | 18.50 | 26.91 |
| | **Total Tax Expenses** | **120.79** | **54.05** | **118.55** | **172.60** |
| 7 | **Profit/ (Loss) from continuing operations (7-8)** | **388.40** | **186.25** | **366.54** | **552.80** |
| | Profit/ (Loss) for a period from dis -continuing operations | 0.00 | 0.00 | 0.00 | 0.00 |
| | Tax Expenses of discountined operations | 0.00 | 0.00 | 0.00 | 0.00 |
| 8 | **Profit/ (Loss) from dis -continuing operations (after tax)** | 0.00 | 0.00 | 0.00 | 0.00 |
| 9 | **Net Profit/(Loss)** | **388.40** | **186.25** | **366.54** | **552.80** |
| 10 | **Paid up Equity Share Capital** | 1,257.20 | 1,257.20 | 926.32 | 1,257.20 |
| 11 | **Reserves and Surplus** | 4,028.51 | 3,652.44 | 1318.55 | 3,652.44 |
| 12 | **Earning Per Share (For continuing operations)** | | | | |
| | (a) Basic | 3.09 | 1.87 | 4.12 | 5.56 |
| | (b) Diluted | 3.09 | 1.87 | 4.12 | 5.56 |

**For and on behalf of the Board of Directors**
**INVICTA DIAGNOSTIC LIMITED**

INVICTA DIAGNOSTIC LIMITED MUMBAI

**Sanket V. Jain**
**Managing Director**
**DIN : 08299039**
**Date : 14/11/2026**
**Place : Mumbai**

**Invicta Diagnostic Limited**

**(CIN: L86100MH2023PLC414723)**

**Reg. Off.:1 GF, Plot 217, Ambavat, Bhavan, N.M Joshi Marg, Delisle Road, Mumbai, Mumbai, Maharashtra, India, 400013**

**Corp. Off.: 1012 10th Floor Hubtown Viva CHS LTD Western Express Highway, Mogra Village Near Shankar Wadi Jogeshwari East, Jogeshwari East, Mumbai, Jogeshwari East, Maharashtra, India, 400060**

Notes

1 The above statements were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14 November 2026

2 These financial results have been prepared in accordance with Accounting Standard ('AS') prescribed under Section 133 of the Companies Act, 2013 read with Companies (Accounting Standards) as amended from time to time and other accounting principles generally accepted and in terms of SEBI (Listing Obligation and Disclosure Requirement) Regulations , 2015.

3 The Company is listed on the SME Platform of NSE. Accordingly:
a. The Company is permitted to prepare financial results under Accounting Standards (AS).
b. Submission of financial results is on a half-yearly basis.

4 The Company is primarily engaged in a single business activity of providing Diagnostic Services. Accordingly, the Company operates in a single business segment. The Company also derives revenue from customers located outside India. However, considering the nature of its operations and the risks and returns associated therewith, the Company does not have any separately reportable geographical segment. Accordingly, separate segment reporting is not applicable under Accounting Standard (AS) 17 – Segment Reporting.

5 Figures of the previous period / year have been regrouped/rearranged, wherever considered necessary.

6 The Company's investment in partnership firm(s)/LLP(s) is carried in the standalone financial statements at cost, subject to assessment for diminution/impairment, if any. The share of accumulated profit/(loss) pertaining to such partnership firm(s)/LLP(s), being retained within the respective entities and reflected in partners' capital/current accounts, has not been separately recognised in the standalone financial results. The same has been considered appropriately in the consolidated financial statements, wherever applicable.

7 There were no investor complaints pending at the beginning or at the end of the period

8 The above financial results are available on the website of the Company at https://www.pcdiagnostics.in/ and website of Stock Exchange www.nseindia.com.

**For, Invicta Diagnostic Limited**




**Mr. Sanket Jain**
**Director**
**DIN: 08299039**
**Date: 14/11/2026**

**INVICTA DIAGNOSTIC LIMITED**
**(CIN NO: L86100MH2023PLC414723)**


**UNAUDITED STANDALONE STATEMENT OF ASSETS & LIABILITIES**

**As on 30th September , 2026**

**(₹ in Lakhs)**

| | Particulars | As at September 30, 2026 | As at September 30, 2025 | As at March 31, 2026 |
|---|---|---|---|---|
| I | **EQUITY AND LIABILITIES** | | | |
| | 1. Shareholders' funds | | | |
| | (a) Share Capital | 1,257.20 | 926.32 | 1,257.20 |
| | (b) Reserves and surplus | 4,028.51 | 1,318.55 | 3,652.44 |
| | **Sub Total Shareholders Funds (A)** | **5,285.71** | **2,244.87** | **4,909.63** |
| | 2. Non-current liabilities | | | |
| | (a) Long-term borrowings | - | 185.91 | - |
| | (b) Deferred Tax liability (Net) | 85.21 | - | 81.38 |
| | (c) Other Non-current Liabilities | - | 72.39 | - |
| | (d) Long-term provisions | 18.03 | 12.56 | 10.82 |
| | **Sub Total Non Current Liabilities (B)** | **103.23** | **270.85** | **92.20** |
| | 3. Current liabilities | | | |
| | (a) Short-term borrowings | - | - | - |
| | (b) Trade payables | | | |
| | i) Due to MSME | - | - | - |
| | ii) Due to Others | 58.11 | 359.10 | 86.17 |
| | (c) Other current liabilities | 64.04 | 29.65 | 58.63 |
| | (d) Short-term provisions | 117.47 | 106.51 | 150.26 |
| | **Sub Total Current Liabilities (C)** | **239.62** | **495.27** | **295.06** |
| | **TOTAL (A+B+C)** | **5,628.57** | **3,011.01** | **5,296.89** |
| II. | **ASSETS** | | | |
| | **1. Non-current assets** | | | |
| | (a) Property, Plant and Equipment and Intangible assets | | | |
| | (i) Property, Plant and Equipment | 820.17 | 829.69 | 741.59 |
| | (ii) Intangible Assets | 0.22 | 0.72 | 0.33 |
| | (b) Non-current investments | 2,849.06 | 1,573.07 | 1,663.57 |
| | (d) Deferred Tax Assets | - | - | - |
| | (c) Long-term loans and advances | - | - | - |
| | (e) Other Non Current Assets | 80.65 | 54.75 | 54.57 |
| | **Total Non Current Assets (A)** | **3,750.10** | **2,458.22** | **2,460.06** |
| | **2. Current assets** | | | |
| | (a) Inventories | 37.66 | 38.40 | 38.68 |
| | (b) Trade receivables | 381.37 | 312.35 | 50.26 |
| | (c) Cash and Bank Balances | 1,176.76 | 68.30 | 2,120.88 |
| | (d) Short-term loans and advances | 280.62 | 133.13 | 620.62 |
| | (e) Other Current Assets | 2.06 | 0.59 | 6.40 |
| | Total Current Assets (B) | **1,878.47** | **552.77** | **2,836.83** |
| | **TOTAL (A+B)** | **5,628.57** | **3,011.01** | **5,296.89** |

**For and on behalf of the Board of Directors**
**INVICTA DIAGNOSTIC LIMITED**




**Sanket V. Jain**
**Managing Director**
**DIN : 08299039**
**Date : 14/11/2026**
**Place : Mumbai**

**INVICTA DIAGNOSTIC LIMITED**
**(CIN NO: L86100MH2023PLC414723)**

**UNAUDITED STANDALONE STATEMENT OF CASH FLOW**

**As on 30th September, 2026**

| Particulars | For the Period / Year Ended On | | |
|---|---|---|---|
| | September 30, 2026 | September 30, 2025 | March 31, 2026 |
| **A. CASH FLOW FROM OPERATING ACTIVITIES** | | | |
| Net Profit before Extraordinary items | 509.19 | 485.10 | 725.41 |
| Adjustment For: | | | |
| (a) Depreciation and Amortization | 83.53 | 58.00 | 148.57 |
| (b) Finance Charges | 3.82 | 1.99 | 4.24 |
| (c) (Gain)/Loss on Sale of Assets | - | - | - |
| (d) Provision for Gratuity | 7.47 | 3.26 | 1.53 |
| (e) Interest & Other income | (83.10) | (87.95) | (113.25) |
| (f) Preliminary Expenses written off | - | - | - |
| (g) Income Tax Paid | - | (150.24) | (142.82) |
| **Operating Profit before Working Capital Changes** | **520.92** | **310.15** | **623.68** |
| Adjustment For : | | | |
| (a) (Increase)/Decrease in Inventories | 1.02 | (2.13) | (2.41) |
| (b) (Increase)/Decrease in Trade Receivables | (331.11) | (73.50) | 188.58 |
| (c) (Increase)/Decrease in Loans & Advances | 203.22 | 21.31 | (466.17) |
| (d) (Increase)/Decrease in Other Assets | 4.34 | (0.33) | (6.14) |
| (e) Increase /(Decrease) in Trade Payables | (28.06) | 330.73 | 57.80 |
| (f) Increase /(Decrease) in Other Liabilities | (7.82) | (3.25) | 25.72 |
| (g) Increase /(Decrease) in Provisions | - | (0.76) | (11.31) |
| (h) Prior Period Adjustments | (12.32) | - | (89.90) |
| **CASH GENERATED FROM OPERATIONS** | **350.18** | **582.21** | **319.84** |
| Less : Direct Taxes paid (Net of Refund) | - | - | - |
| CASH FLOW BEFORE EXTRAORDINARY ITEMS | **350.18** | **582.21** | **319.84** |
| **NET CASH FROM OPERATING ACTIVITIES (A)** | **350.18** | **582.21** | **319.84** |
| **B. CASH FLOW FROM INVESTING ACTIVITIES** | | | |
| (a) Purchase of Fixed Assets | (162.00) | (507.76) | (509.84) |
| (b) Sale of Fixed Assets | - | - | - |
| (c) (Increase) / Decrease in Investment | (1,185.49) | (772.79) | (863.29) |
| (d) (Increase ) / Decrease in Long term loans and advances | - | - | - |
| (e) (Increase ) / Decrease in Non Current Assets | (26.08) | 0.16 | 0.33 |
| (f) Interest and other income | 83.10 | 87.96 | 113.25 |
| **NET CASH FROM INVESTING ACTIVITIES (B)** | **(1,290.48)** | **(1,192.44)** | **(1,259.55)** |
| **C. CASH FLOW FROM FINANCING ACTIVITIES** | | | |
| (a) Increase/(Decrease) in Long Term Borrowing | - | - | - |
| (b) Increase/(Decrease) in Short Term Borrowing | - | - | - |
| (c) Increase / ( Decrease ) in Partners Current Account | - | - | - |
| (d) Fresh Capital Infusion/(Withdrawal) | - | 600.13 | 2,983.64 |
| (e) Interest Paid | (3.82) | (1.99) | (4.24) |
| **NET CASH FLOW IN FINANCING ACTIVITIES (C)** | **(3.82)** | **598.14** | **2,979.39** |
| **NET INCREASE IN CASH & CASH EQUIVALENTS (A)+(B)+(C )** | (944.12) | (12.09) | 2,040.49 |
| **OPENING BALANCE – CASH & CASH EQUIVALENT** | **2,120.88** | **80.39** | **80.39** |
| **CLOSING BALANCE - CASH & CASH EQUIVALENT** | **1,176.76** | **68.30** | **2,120.88** |

***For and on Behalf of the Board of Directors***
**INVICTA DIAGNOSTIC LIMITED**

**Sanket V. Jain**
**Director**
**DIN : 08299039**
**Date : 14/11/2026**
**Place : Mumbai**

INVICTA DIAGNOSTIC LIMITED ★ MUMBAI

KANAK RATHOD & CO.
CHARTERED ACCOUNTANTS

K. B. RATHOD B.COM., F.C.A.

Flat No. 203, New Swapnalok C.H.S. Ltd.,
Natakwala Lane, S.V. Rd., Borivali (West),
Mumbai : 400 092.
Mob: 9869243109.
E-mail: cakanak51@gmail.com

**Independent Auditor's Limited Review Report on the Half yearly Unaudited Consolidated Financial Results of the Company Pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as Amended**

To,
The Board of Directors of
Invicta Diagnostic Limited.

Limited Review Report on the Unaudited **Consolidated Financial Results**

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Invicta Diagnostic Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer below table for the list of entities included in the Statement) for the half year ended 30 September 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

**List of entities included in statement**

| Sr. No. | Name | Status |
|---|---|---|
| 1. | Primacare Healthcare LLP | Subsidiary |
| 2. | PCD Diagnostics LLP | Subsidiary |
| 3. | Pratham MRI & CT Scan Centre | Subsidiary |
| 4. | Invicta Medical LLP | Subsidiary |
| 5. | Primacare Diagnostic LLP | Subsidiary |
| 6. | Porteus Medical LLP | Subsidiary |
| 7. | Porteus Pathogenius LLP | Sub-Subsidiary |
| 8. | Shegaon Diagnostic LLP | Subsidiary |
| 9. | Invicta Diagnostic Healthplus LLP | Subsidiary |
| 10. | Invicta Diagnostic Lifecare LLP | Subsidiary |
| 11. | Mscribeit Infotech LLP | Associate |
| 12. | Vinchurkar Diagnostics Private Limited | Subsidiary |




2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25, Interim Financial Reporting ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India, and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, and upon consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We did not review the interim financial results of Vinchurkar Diagnostics Private Limited (subsidiary) as mentioned above, whose financial information (before eliminating intercompany transactions and balances) reflect, total revenues of Rs. 236.15 lakhs, total net profit after tax of Rs. 30.75 lakhs for the half year ended 30th September 2026, as considered in the Statement and total revenues of Rs. 2424.65 lakhs, total net profit after tax of Rs. 232.14 lakhs for the half year ended 30th September 2026. Financial statements of this subsidiary have been prepared under generally accepted accounting principles and are reviewed by the other auditors. Review reports issued by such auditors have been furnished to us by the



management. Our opinion on the financial statement, in so far as it relates to the amounts and disclosures of the aforesaid subsidiaries is based on the reports of other auditors and is not modified in respect of our reliance on the work done and the reports of the other auditor.

**For Kanak Rathod & Co.**
**Chartered Accountants**
**Firm Regn No: 104700W**




**Kanak Rathod**
**Proprietor**
**Membership No: 032833**
**Date: 14/11/2026**
**Mumbai**
**UDIN :** 26032833GNJZDM8067

## Invicta Diagnostic Limited

(CIN: L86100MH2023PLC414723)

Reg. Off.:1 GF, Plot 217, Ambavat, Bhavan, N.M Joshi Marg, Delisle Road, Mumbai, Mumbai, Maharashtra, India, 400013

Corp. Off.: 1012 10th Floor Hubtown Viva CHS LTD Western Express Highway, Mogra Village Near Shankar Wadi Jogeshwari East, Jogeshwari East, Mumbai, Jogeshwari East, Maharashtra, India, 400060

Tel: 022-4971 0036 Email-Id: info@pcdiagnostics.in Website: https://www.pcdiagnostics.in/

**UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE HALF YEAR ENDED ON 30.09.2026**

(Amount in Lakhs)

| SN | Particulars | Half year ended | Preceding Half year ended | Corresponding Half year ended in the previous year | Current Year |
|---|---|---|---|---|---|
| | | 30-Sep-26 | 31-Mar-26 | 30-Sep-25 | 31-Mar-26 |
| | | Unaudited | Audited | Unaudited | Audited |
| 1 | **Income** | | | | |
| | (a)Revenue From Operations | 2424.65 | 1,540.63 | 1694.73 | 3235.36 |
| | (b)Other Income | 50.57 | 55.60 | 13.23 | 68.83 |
| | **Total Income** | **2,475.21** | **1,596.23** | **1,707.96** | **3,304.19** |
| 2 | **Expenses** | | | | |
| | (a) Cost of materials consumed | 0.00 | 0.00 | 0.00 | 0.00 |
| | (b) Purchase of consumables | 188.38 | 140.77 | 140.89 | 281.66 |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 5.94 | (3.20) | -5.92 | (9.12) |
| | (d) Finance Cost | 10.79 | 9.27 | 10.26 | 19.53 |
| | (e) Employee Benefits Expenses | 329.52 | 315.93 | 173.19 | 489.12 |
| | (f) Depreciation and amortisation expense | 283.62 | 188.09 | 136.62 | 324.71 |
| | (g) Other expenses | 1233.30 | 787.37 | 710.07 | 1,497.44 |
| | **Total Expenses** | **2051.54** | **1438.23** | **1165.11** | **2603.34** |
| 3 | **Profit / (Loss) before exceptional and extraordinary items and tax** | **423.67** | **158.00** | **542.85** | **700.85** |
| | Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 |
| 4 | **Profit / (Loss) before extraordinary items and tax (3-4)** | **423.67** | **158.00** | **542.85** | **700.85** |
| | Extraordinary Items | 0.00 | 0.00 | 0.00 | 0.00 |
| 5 | **Profit/ (Loss) before Tax (5-6)** | **423.67** | **158.00** | **542.85** | **700.85** |
| 6 | **Tax Expenses** | | | | |
| | (a) Current Tax | 142.58 | 51.06 | 110.30 | 161.36 |
| | (b) Deferred Tax | 48.95 | 28.02 | 24.14 | 52.16 |
| | **Total Tax Expenses** | **191.54** | **79.09** | **134.44** | **213.53** |
| 7 | **Profit/ (Loss) from continuing operations (7-8)** | **232.14** | **78.91** | **408.41** | **487.32** |
| | Profit/ (Loss) for a period from dis -continuing operations | 0.00 | 0.00 | 0.00 | 0.00 |
| | Tax Expenses of discountined operations | 0.00 | 0.00 | 0.00 | 0.00 |
| 8 | **Profit/ (Loss) from dis -continuing operations (after tax)** | 0.00 | 0.00 | 0.00 | 0.00 |
| 9 | **Net Profit/(Loss)** | **232.14** | **78.91** | **408.41** | **487.32** |
| | Profit Pertaining to Parent Company | 252.52 | 90.63 | 400.00 | 490.63 |
| | Profit Pertaining to Parent Minority Interest | -20.38 | -11.72 | 8.41 | -3.31 |
| 10 | **Paid up Equity Share Capital** | 1,257.20 | 1,257.20 | 926.32 | 1,257.20 |
| 11 | **Reserves and Surplus** | 4,496.59 | 3,735.06 | 1442.06 | 3,735.06 |
| 12 | **Earning Per Share (For continuing operations)** | | | | |
| | (a) Basic | 2.01 | 0.79 | 4.59 | 4.90 |
| | (b) Diluted | 2.01 | 0.79 | 4.59 | 4.90 |

**For and on behalf of the Board of Directors**
**INVICTA DIAGNOSTIC LIMITED**

INVICTA DIAGNOSTIC LIMITED MUMBAI

**Sanket V. Jain**
**Managing Director**
**DIN : 08299039**
**Date : 14/11/2026**
**Place : Mumbai**

**Invicta Diagnostic Limited**

**(CIN: L86100MH2023PLC414723)**

**Reg. Off.:1 GF, Plot 217, Ambavat, Bhavan, N.M Joshi Marg, Delisle Road, Mumbai, Mumbai, Maharashtra, India, 400013**

**Corp. Off.: 1012 10th Floor Hubtown Viva CHS LTD Western Express Highway, Mogra Village Near Shankar Wadi Jogeshwari East, Jogeshwari East, Mumbai, Jogeshwari East, Maharashtra, India, 400060**

Notes

1. The above statements were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14th November 2026.
2. These financial results have been prepared in accordance with Accounting Standard ('AS') prescribed under Section 133 of the Companies Act, 2013 read with Companies (Accounting Standards) as amended from time to time and other accounting principles generally accepted and in terms of SEBI (Listing Obligation and Disclosure Requirement) Regulations , 2015.
3. The Company is listed on the SME Platform of NSE. Accordingly:
   a. The Company is permitted to prepare financial results under Accounting Standards (AS).
   b. Submission of financial results is on a half-yearly basis.
4. The Group is primarily engaged in a single business activity of providing diagnostic services. Accordingly, the group operates in a single business segment. The Group also derives revenue from customers located outside India. However, considering the nature of its operations and the risks and returns associated therewith, the group does not have any separately reportable geographical segment. Accordingly, separate segment reporting is not applicable under Accounting Standard (AS) 17 – Segment Reporting
5. Figures of the previous period / year have been regrouped/rearranged, wherever considered necessary.
6. The Company's investment in partnership firm(s)/LLP(s) is carried in the standalone financial statements at cost, subject to assessment for diminution/impairment, if any. The share of accumulated profit/(loss) pertaining to such partnership firm(s)/LLP(s), being retained within the respective entities and reflected in partners' capital/current accounts, has not been separately recognised in the standalone financial results. The same has been considered appropriately in the consolidated financial statements, wherever applicable.
7. There were no investor complaints pending at the beginning or at the end of the period
8. The above financial results are available on the website of the Company at https://www.pcdiagnostics.in/ and website of Stock Exchange www.nseindia.com.

**For and on behalf of the Board of Directors**
**INVICTA DIAGNOSTIC LIMITED**

**Mr. Sanket Jain**
**Managing Director**
**DIN: 08299039**
**Date: 14/11/2026**

INVICTA DIAGNOSTIC LIMITED MUMBAI

**INVICTA DIAGNOSTIC LIMITED**
**(CIN NO: L86100MH2023PLC414723)**

**UNAUDITED CONSOLIDATED STATEMENT OF ASSETS & LIABILITIES**

**As on 30th September , 2026**

**(₹ in Lakhs)**

| | Particulars | As at September 30, 2026 | As at September 30, 2025 | As at March 31, 2026 |
|---|---|---|---|---|
| I | **EQUITY AND LIABILITIES** | | | |
| | 1 Shareholders' funds | | | |
| | (a) Share Capital | 1,257.20 | 926.32 | 1,257.20 |
| | (b) Reserves and surplus | 4,496.59 | 1,442.06 | 3,735.06 |
| | **Sub Total Shareholders Funds (A)** | **5,753.79** | **2,368.38** | **4,992.25** |
| | 2. Non-current liabilities | | | |
| | (a) Long-term borrowings | 106.06 | 372.32 | 124.11 |
| | (b) Deferred Tax liability (Net) | 207.98 | 152.96 | 181.74 |
| | (c) Other Non-current Liabilities | - | - | - |
| | (d) Long-term provisions | 18.03 | 12.56 | 10.82 |
| | **Sub Total Non Current Liabilities (B)** | **332.07** | **537.83** | **316.66** |
| | 3. Current liabilities | | | |
| | (a) Short-term borrowings | 5.00 | - | 243.00 |
| | (b) Trade payables | | | |
| | i) Due to MSME | - | - | - |
| | ii) Due to Others | 164.28 | 403.69 | 190.09 |
| | (c) Other current liabilities | 79.70 | 56.48 | 70.12 |
| | (d) Short-term provisions | 194.49 | 123.65 | 212.74 |
| | **Sub Total Current Liabilities (C)** | **443.47** | **583.82** | **715.96** |
| | **TOTAL (A+B+C)** | **6,529.33** | **3,490.03** | **6,024.87** |
| II. | **ASSETS** | | | |
| | **1. Non-current assets** | | | |
| | (a) Property, Plant and Equipment and Intangible assets | | | |
| | (i) Property, Plant and Equipment | 3,038.96 | 1,558.01 | 1,918.95 |
| | (ii) Intangible Assets | 306.44 | 0.92 | 0.85 |
| | (b) Non-current investments | 810.95 | 813.66 | 619.75 |
| | (d) Deferred Tax Assets | - | - | - |
| | (c) Long-term loans and advances | - | - | - |
| | (e) Other Non Current Assets | 174.29 | 106.19 | 54.57 |
| | **Total Non Current Assets (A)** | **4,330.64** | **2,478.78** | **2,594.12** |
| | **2. Current assets** | | | |
| | (a) Inventories | 54.51 | 56.18 | 59.38 |
| | (b) Trade receivables | 358.71 | 269.04 | 57.25 |
| | (c) Cash and Bank Balances | 1,422.40 | 193.82 | 2,221.33 |
| | (d) Short-term loans and advances | 314.03 | 491.61 | 1,049.95 |
| | (e) Other Current Assets | 49.04 | 0.59 | 42.83 |
| | **Total Current Assets (B)** | **2,198.69** | **1,011.24** | **3,430.75** |
| | **TOTAL (A+B)** | **6,529.33** | **3,490.03** | **6,024.87** |

**For and on behalf of the Board of Directors**
**INVICTA DIAGNOSTIC LIMITED**

**Sanket V. Jain**
**Managing Director**
**DIN : 08299039**
**Date : 14/11/2026**
**Place : Mumbai**

INVICTA DIAGNOSTIC LIMITED * MUMBAI

**INVICTA DIAGNOSTIC LIMITED**
**(CIN NO: L86100MH2023PLC414723)**

**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW**

**As on 30th September, 2026**

| Particulars | For the Period / Year Ended On | | |
|---|---|---|---|
| | September 30, 2026 | September 30, 2025 | March 31, 2026 |
| **A. CASH FLOW FROM OPERATING ACTIVITIES** | | | |
| Net Profit before Extraordinary items | 423.67 | 542.85 | 700.84 |
| Adjustment For: | - | - | - |
| (a) Depreciation and Amortization | 283.62 | 136.62 | 324.71 |
| (b) Finance Charges | 10.79 | 10.26 | 19.53 |
| (c) Income from Mutual Fund | (16.02) | | (34.36) |
| (d) Provision for Gratuity | 7.47 | 3.26 | 1.53 |
| (e) Interest & Other income | (34.55) | - | (34.46) |
| (f) Miscellaneous Income | - | - | (0.01) |
| (g) Loss on sale of fixed assets | 3.18 | - | - |
| **Operating Profit before Working Capital Changes** | **678.16** | **692.99** | **977.77** |
| Adjustment For : | | | |
| (a) (Increase)/Decrease in Inventories | 4.87 | (5.92) | (9.12) |
| (b) (Increase)/Decrease in Trade Receivables | (301.45) | (123.42) | 88.36 |
| (c) (Increase)/Decrease in Loans & Advances | 735.91 | (265.36) | (823.70) |
| (d) (Increase)/Decrease in Other Assets | (6.21) | (0.10) | (42.34) |
| (e) Increase /(Decrease) in Trade Payables | (25.82) | 362.00 | 148.40 |
| (f) Increase /(Decrease) in Other Liabilities | 9.59 | 0.12 | 13.76 |
| (g) Increase /(Decrease) in Provisions | (11.07) | (3.95) | 42.47 |
| **CASH GENERATED FROM OPERATIONS** | **1,083.98** | **656.36** | **395.60** |
| Less : Direct Taxes paid (Net of Refund) | (150.02) | (154.52) | (102.40) |
| CASH FLOW BEFORE EXTRAORDINARY ITEMS | **933.97** | **501.84** | **293.20** |
| **NET CASH FROM OPERATING ACTIVITIES (A)** | **933.97** | **501.84** | **293.20** |
| **B. CASH FLOW FROM INVESTING ACTIVITIES** | | | |
| (a) Purchase of Fixed Assets | (1,406.70) | (737.40) | (1,296.12) |
| (b) Acquisition of subsidiary – goodwill on consolidation | (305.71) | - | - |
| (c) Sale of Fixed Assets/ Adjustment on Account of Consolidation | - | - | 9.76 |
| (d) (Increase) / Decrease in Investment | (191.20) | (380.28) | (186.37) |
| (e) (Increase ) / Decrease in Non Current Assets | (119.72) | (14.85) | 36.77 |
| (f) Interest and other income | 34.55 | - | 34.47 |
| (g) Income From Mutual Fund | 16.02 | - | 34.36 |
| **NET CASH FROM INVESTING ACTIVITIES (B)** | **(1,972.76)** | **(1,132.53)** | **(1,367.13)** |
| **C. CASH FLOW FROM FINANCING ACTIVITIES** | | | |
| (a) Increase/(Decrease) in Long Term Borrowing | (18.04) | 18.48 | (229.73) |
| (b) Fresh Capital Infusion/Withdrawal | - | 600.13 | 2,983.64 |
| (c) Increase/(Decrease) in Short Term Borrowing | (238.00) | - | 243.00 |
| (d) Interest Paid | (10.79) | (10.26) | (19.53) |
| (e) Adjustment on Consolidation | (32.62) | - | 129.93 |
| (f) Adjustment for Minority Interest | 539.32 | - | (28.21) |
| **NET CASH FLOW IN FINANCING ACTIVITIES (C)** | **239.86** | **608.36** | **3,079.10** |
| **NET INCREASE IN CASH & CASH EQUIVALENTS (A)+(B)+(C )** | (798.93) | (22.34) | 2,005.17 |
| **OPENING BALANCE – CASH & CASH EQUIVALENT** | **2,221.33** | **216.16** | **216.16** |
| **CLOSING BALANCE - CASH & CASH EQUIVALENT** | **1,422.40** | **193.82** | **2,221.33** |

**For and on Behalf of the Board of Directors**
**INVICTA DIAGNOSTIC LIMITED**

**Sanket V. Jain**
**Managing Director**
**DIN : 08299039**
**Date : 14/11/2026**
**Place : Mumbai**

INVICTA DIAGNOSTIC LIMITED MUMBAI

**INVICTA DIAGNOSTIC LIMITED**
CIN: L86100MH2023PLC414723
**Registered Office:** 1 Ground Floor, Plot No. 217, Ambavat Bhavan, N.M Joshi Marg, Delisle Road, Mumbai – 400 013. | Email: info@pcdiagnostics.in | Contact: 022 4971 0036

**November 14th, 2026**

**National Stock Exchange of India Limited**
Exchange Plaza, 5th Floor, C-1,
Block G, Bandra Kurla Complex,
Bandra (E), Mumbai 400051

**NSE SYMBOL: INVICTA**
**ISIN: INE0XJ501010**

**Subject: Statement of deviation/variation in utilization of funds raised through Initial Public Offer for the half year ended on September 30th, 2026.**

**Dear Sir/Madam,**

With reference to captioned subject and pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, please find enclosed herewith statement of Deviation/variation in utilization of funds raised through Initial Public Offer for the half year ended on September 30th, 2026.

We would hereby further inform you that the said statement is reviewed by the Audit Committee in its meeting held on Saturday, November 14, 2026.

You are requested to take the same on record.

Thanking you,

Yours Faithfully,
**For Invicta Diagnostic Limited**

Sanket Vinod Jain
Digitally signed by Sanket Vinod Jain
Date: 2026.11.14 20:19:21 +05'30'

**Sanket Vinod Jain**
**Chairman and Managing Director**
**DIN: 08299039**
**Place: Mumbai**

KANAK RATHOD & CO.
CHARTERED ACCOUNTANTS

K. B. RATHOD B.COM., F.C.A.

Flat No. 203, New Swapnalok C.H.S. Ltd.,
Natakwala Lane, S.V. Rd., Borivali (West),
Mumbai : 400 092.
Tele: 35668114 Mob: 9869243109.
E-mail: cakanak51@gmail.com

**Date: November 14, 2026**

**Certificate on Disclosure for utilization of issue proceeds for Listed Entities on NSE EMERGE in the case of Invicta Diagnostic Limited ("the company") (CIN: L86100MH2023PLC414723) having registered address at 1 GF, Plot 217, Ambavat, Bhavan, N.M Joshi Marg, Delisle Road, Mumbai, Maharashtra, India, 400013**

In connection with the Disclosure for utilization of issue proceeds for Listed Entities on NSE EMERGE, we have verified the information mentioned in **Annexure A** with respect to the Company, extracted from the standalone financial statements of the company for the half-year ended September 30, 2026 and other relevant records the Company prepared and produced before us by the Board of Directors of the Company. The information mentioned in **Annexure A** was approved by the audit committee and taken on record by the Board of Directors of the Company in their meeting held on November 14, 2026.

We hereby confirm that while providing this certificate we have complied with the Code of Ethics issued by the Institute of Chartered Accountants of India. This certificate is being provided in compliance with NSE Circular No. NSE/CML/2024/23 dated 05/09/2024

**Annexure A**

**Statement of Utilisation of IPO Proceeds for the Half Year Ended September 30, 2026**

(₹ in Lakhs)

| Sr. No. | Particulars | Amount (₹ Lakhs) |
|---|---|---|
| 1 | Total amount raised through Initial Public Offer | 2,812.48 |
| 2 | Less: Issue-related expenses | 293.69 |
| 3 | Net proceeds from IPO | 2,518.79 |
| 4 | Unutilised issue-related expenses reallocated towards General Corporate Purposes | 15.10 |
| 5 | **Total funds available for utilisation, including reallocation** | **2,533.89** |

**A. Object-wise utilisation of IPO proceeds**

| Sr. No. | Objects of the Issue as revised in EGM dated 17.04.2026 | Revised Allocation | Cumulative Utilisation up to 30.09.2026 | Unutilised Balance |
|---|---|---|---|---|
| 1 | To commence atleast five diagnostic centres in Maharashtra directly or through subsidiary entities including Diagnostic Centre at Object No. 3. | 1,351.33 | 775.36 | 575.97 |
| 2 | General Corporate Purposes | 422.56 | 263.33 | 159.23 |

KANAK RATHOD & CO. M. No. 32053 MUMBAI CHARTERED ACCOUNTANTS

KANAK RATHOD & CO.
CHARTERED ACCOUNTANTS

K. B. RATHOD B.COM., F.C.A.

Flat No. 203, New Swapnalok C.H.S. Ltd.,
Natakwala Lane, S.V. Rd., Borivali (West),
Mumbai : 400 092.
Tele: 35668114 Mob: 9869243109.
E-mail: cakanak51@gmail.com

| | | | | |
|---|---|---|---|---|
| 3 | Acquisition of up to 95% equity stake in Vinchurkar Diagnostics Private Limited (Nashik Centre) | 760.00 | 408.00 | 352.00 |
| | **Total** | **2,533.89** | **1446.69** | **1087.20** |

Note: Unutilised balance is parked in Fixed Deposits and Current Accounts with Banks

For and Behalf of,
**M/s Kanak Rathod & Co**
**Chartered Accountants**




**CA KANAK RATHOD**
**M. No. 032833**
**FRN No. 104700W**
UDIN No. 26032833XAAYSL9260

**Annexure I**

**STATEMENT OF DEVIATION / VARIATION IN UTILISATION OF IPO PROCEEDS**
**For the quarter ended September 30, 2026**

| **Particulars** | **Details** |
|---|---|
| Name of Listed Entity | Invicta Diagnostic Limited |
| Mode of Fund Raising | Public Issue |
| Date of Raising Funds | December 4, 2025 |
| Amount Raised | Rs. 2,812.48 Lakhs |
| Report filed for Quarter ended | September 30, 2026 |
| Monitoring Agency | Not Applicable |
| Monitoring Agency Name, if applicable | Not Applicable |
| Is there a Deviation / Variation in use of funds raised? | Yes |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders | Yes |
| If Yes, Date of Shareholder Approval | April 17, 2026 |
| Comments of the Audit Committee after review | None |
| Comments of the Auditors, if any | None |

**Explanation for the Deviation / Variation**

1. The Company had obtained approval of its shareholders at the Extra-Ordinary General Meeting held on April 17, 2026, for variation in the objects and terms of utilisation of the IPO proceeds.

2. The variation included revision in the allocation towards capital expenditure for setting up diagnostic centres in Maharashtra, revision in the allocation towards General Corporate Purposes (GCP) and introduction of a new object for acquisition of up to 95% equity stake in Vinchurkar Diagnostics Private Limited, Nashik Centre.

3. Further, the unutilised amount of Rs. 15.10 Lakhs from the issue-related expenses was reallocated towards General Corporate Purposes.

4. The revised allocation of IPO proceeds, as approved by the shareholders, and the utilisation thereof up to September 30, 2026, are set out below.

**Objects for which funds have been raised and where there has been a deviation, in the following table**

*(Rs. in Lakhs)*

| Sr. No. | Original Object | Modified Object, if any | Original Allocation | Modified Allocation | Funds Utilised up to September 30, 2026 | Amount of Deviation / Variation | Remarks, if any |
|---|---|---|---|---|---|---|---|
| 1 | Funding capital expenditure for purchase of medical equipment for five new diagnostic centres in Maharashtra | To commence at least five diagnostic centres in Maharashtra directly or through subsidiary entities, including the diagnostic centre covered under Object No. 3 | 2,111.33 | 1,351.33 | 775.36 | (760.00) | Allocation reduced and allocated to Object No. 3 pursuant to shareholders' approval |
| 2 | General Corporate Purposes | General Corporate Purposes | 407.46 | 422.56 | 263.33 | 15.10 | Includes reallocation of Rs. 15.10 Lakhs from unutilised issue-related expenses |
| 3 | — | Acquisition of up to 95% equity stake in Vinchurkar Diagnostics Private Limited (Nashik Centre) | — | 760.00 | 408.00 | 760.00 | New object introduced and amount allocated from Object No. 1 pursuant to shareholders' approval |
| 4 | Issue-related expenses | — | 293.69 | — | 278.59* | (15.10) | Unutilised amount of Rs. 15.10 Lakhs reallocated towards GCP |
| **Total** | | | **2,812.48** | **2,533.89** | **1,725.28** | 0.00 | |

**For Invicta Diagnostic Limited**

Sanket Vinod Jain

Digitally signed by Sanket Vinod Jain
Date: 2026.11.14 20:21:08 +05'30'

**Sanket Vinod Jain**
**Chairman and Managing Director**
**DIN: 08299039**

**Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)**

| Sr. No. | Details of the party (listed entity /subsidiary) entering into the transaction | | Details of the counterparty | | | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit committee | Remarks on approval by audit committee | Value of the related party transaction ratified by the audit committee | Date of Audit Committee Meeting where the ratification was approved | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | | | | | | | | Opening balance | Closing balance |
| | Add Delete | | | | | | | | | | | | | |
| 1 | Invicta Diagnostic Limited | | Dipika Jain | | Relative of Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 13.12 | 0.00 | 0.00 |
| 2 | Invicta Diagnostic Limited | | Ketan Jain | | Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 11.51 | 0.00 | 0.00 |
| 3 | Invicta Diagnostic Limited | | Sanket Jain | | Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 5.16 | 0.00 | 0.00 |
| 4 | Invicta Diagnostic Limited | | Monal Jain | | Relative of Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 6.21 | 0.00 | 0.00 |
| 5 | Invicta Diagnostic Limited | | Konica Srivastava | | Relative of KMP | Purchase of goods or services | | | Approved by Audit Committee where required | | | 5.70 | 0.00 | 0.00 |
| 6 | Invicta Diagnostic Limited | | Kushal Koli | | Promoter | Purchase of goods or services | | | Approved by Audit Committee where required | | | 22.52 | 0.00 | 0.00 |
| 7 | Invicta Diagnostic Limited | | Rohit Srivastava | | KMP | Purchase of goods or services | | | Approved by Audit Committee where required | | | 1.20 | 0.00 | 0.00 |
| 8 | Invicta Diagnostic Limited | | Rohit Srivastava | | KMP | Remuneration | | 4.80 | Approved by Audit Committee where required | | | 4.80 | 0.00 | 0.00 |
| 9 | Invicta Diagnostic Limited | | Konica Srivastava | | Relative of KMP | Remuneration | | 7.20 | Approved by Audit Committee where required | | | 2.40 | 0.00 | 0.00 |
| 10 | Invicta Diagnostic Limited | | Ketan Jain | | Director | Remuneration | | 6.00 | Approved by Audit Committee where required | | | 3.00 | 0.00 | 0.00 |
| 11 | Invicta Diagnostic Limited | | Sanket Jain | | Director | Remuneration | | 6.00 | Approved by Audit Committee where required | | | 3.20 | 0.00 | 0.00 |
| 12 | Invicta Diagnostic Limited | | Primacare Healthcare LLP | | Subsidiary | Purchase of goods or services | | 2000.00 | Approved by Audit Committee where required | | | 14.00 | 0.00 | 0.00 |
| 13 | Invicta Diagnostic Limited | | Payal Jain | | Promoter Group | Remuneration | | 60.00 | Approved by Audit Committee where required | | | 10.50 | 0.00 | 0.00 |
| 14 | Invicta Diagnostic Limited | | Invicta Medical LLP | | Subsidiary | Sale of goods or services | | 2000.00 | Approved by Audit Committee where required | | | 2.56 | 0.00 | 0.00 |
| 15 | Invicta Diagnostic Limited | | Invicta Medical LLP | | Subsidiary | Sale of goods or services | | 2000.00 | Approved by Audit Committee where required | | | 0.23 | 0.00 | 0.00 |
| 16 | Invicta Diagnostic Limited | | PCD Diagnostic LLP | | Subsidiary | Sale of goods or services | | 2000.00 | Approved by Audit Committee where required | | | 1.54 | 0.00 | 0.00 |
| 17 | Invicta Diagnostic Limited | | Porteus Medical LLP | | Subsidiary | Sale of goods or services | | 2000.00 | Approved by Audit Committee where required | | | 3.58 | 0.00 | 0.00 |
| 18 | Invicta Diagnostic Limited | | Pratham Mri and CT Scan Center | | Subsidiary | Sale of goods or services | | 2000.00 | Approved by Audit Committee where required | | | 26.41 | 0.00 | 0.00 |
| 19 | Invicta Diagnostic Limited | | Primacare Diagnostic LLP | | Subsidiary | Sale of goods or services | | 2000.00 | Approved by Audit Committee where required | | | 11.51 | 0.00 | 0.00 |
| 20 | Invicta Diagnostic Limited | | Primacare Diagnostic LLP | | Subsidiary | Sale of goods or services | | 2000.00 | Approved by Audit Committee where required | | | 1.51 | 0.00 | 0.00 |
| 21 | Invicta Diagnostic Limited | | Primacare Healthcare LLP | | Subsidiary | Sale of goods or services | | 2000.00 | Approved by Audit Committee where required | | | 4.26 | 0.00 | 0.00 |
| 22 | Invicta Diagnostic Limited | | Vinchurkar Diagnostics Pvt Ltd | | Subsidiary | Sale of goods or services | | | Approved by Audit Committee where required | | | 32.32 | 0.00 | 0.00 |
| 23 | PCD Diagnostic LLP | | Dipika Jain | | Promoter Group | Purchase of goods or services | | | Approved by Audit Committee where required | | | 0.08 | 0.00 | 0.00 |
| 24 | PCD Diagnostic LLP | | Ketan Jain | | Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 0.00 | 0.00 | 0.00 |
| 25 | PCD Diagnostic LLP | | Kushal Koli | | Promoter Group | Purchase of goods or services | | | Approved by Audit Committee where required | | | 0.03 | 0.00 | 0.00 |
| 26 | PCD Diagnostic LLP | | Sanket Jain | | Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 0.38 | 0.00 | 0.00 |
| 27 | PCD Diagnostic LLP | | Primacare Healthcare LLP | | Subsidiary | Purchase of goods or services | | | Approved by Audit Committee where required | | | 9.00 | 0.00 | 0.00 |

| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28 | Porteus Medical LLP | | Vishwajeet Burungale | | Designated Parter | Purchase of goods or services | | | Approved by Audit Committee where required | | | 9.32 | 0.00 | 0.00 |
| 29 | Porteus Medical LLP | | Khandelwal Healthcare Pvt Ltd | | Promoter Group | Purchase of goods or services | | | Approved by Audit Committee where required | | | 0.08 | 0.00 | 0.00 |
| 30 | Porteus Medical LLP | | Arvind Burungale | | Designated Parter | Purchase of goods or services | | | Approved by Audit Committee where required | | | 4.42 | 0.00 | 0.00 |
| 31 | Pratham Mri and CT Scan Center | | Narayan Chavan | | Partner | Purchase of goods or services | | | Approved by Audit Committee where required | | | 0.69 | 0.00 | 0.00 |
| 32 | Pratham Mri and CT Scan Center | | Kushal Koli | | Promoter Group | Purchase of goods or services | | | Approved by Audit Committee where required | | | 10.11 | 0.00 | 0.00 |
| 33 | Pratham Mri and CT Scan Center | | Usha Chavan | | Relative of Partner | Purchase of goods or services | | | Approved by Audit Committee where required | | | 6.75 | 0.00 | 0.00 |
| 34 | Pratham Mri and CT Scan Center | | Narayan Chavan | | Partner | Purchase of goods or services | | | Approved by Audit Committee where required | | | 7.97 | 0.00 | 0.00 |
| 35 | Pratham Mri and CT Scan Center | | Aditi Jain | | Promoter Group | Remuneration | | 60.00 | Approved by Audit Committee where required | | | 12.00 | 0.00 | 0.00 |
| 36 | Pratham Mri and CT Scan Center | | Komal Jain | | Relative of Director | Remuneration | | 60.00 | Approved by Audit Committee where required | | | 12.00 | 0.00 | 0.00 |
| 37 | Primacare Diagnostic LLP | | Kushal Koli | | Promoter Group | Purchase of goods or services | | | Approved by Audit Committee where required | | | 1.05 | 0.00 | 0.00 |
| 38 | Primacare Diagnostic LLP | | Dipika Jain | | Promoter Group | Purchase of goods or services | | | Approved by Audit Committee where required | | | 0.66 | 0.00 | 0.00 |
| 39 | Primacare Diagnostic LLP | | Sanket Jain | | Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 0.01 | 0.00 | 0.00 |
| 40 | Primacare Diagnostic LLP | | Khandelwal Healthcare Pvt Ltd | | Promoter Group | Purchase of goods or services | | | Approved by Audit Committee where required | | | 1.31 | 0.00 | 0.00 |
| 41 | Primacare Diagnostic LLP | | Ketan Jain | | Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 0.65 | 0.00 | 0.00 |
| 42 | Primacare Diagnostic LLP | | Monal Jain | | Relative of Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 2.00 | 0.00 | 0.00 |
| 43 | Primacare Healthcare LLP | | Dipika Jain | | Relative of Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 1.20 | 0.00 | 0.00 |
| 44 | Primacare Healthcare LLP | | Ketan Jain | | Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 1.50 | 0.00 | 0.00 |
| 45 | Primacare Healthcare LLP | | Sanket Jain | | Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 41.81 | 0.00 | 0.00 |
| 46 | Primacare Healthcare LLP | | Badal Naredi HUF | | Promoter Group | Purchase of goods or services | | | Approved by Audit Committee where required | | | 9.00 | 0.00 | 0.00 |
| 47 | Primacare Healthcare LLP | | Rohit Srivastava HUF | | Promoter Group | Purchase of goods or services | | | Approved by Audit Committee where required | | | 9.90 | 0.00 | 0.00 |
| 48 | Primacare Healthcare LLP | | Garima Naredi | | Promoter Group | Remuneration | | 60.00 | Approved by Audit Committee where required | | | 14.60 | 0.00 | 0.00 |
| 49 | Vinchurkar Diagnostics Pvt Ltd | | Khandelwal Healthcare Pvt Ltd | | Promoter Group | Purchase of goods or services | | | Approved by Audit Committee where required | | | 7.78 | 0.00 | 0.00 |
| 50 | Vinchurkar Diagnostics Pvt Ltd | | Kshitija Vinchurkar | | Relative of Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 0.05 | 0.00 | 0.00 |
| 51 | Vinchurkar Diagnostics Pvt Ltd | | Kushal Koli | | Promoter Group | Purchase of goods or services | | | Approved by Audit Committee where required | | | 0.91 | 0.00 | 0.00 |
| 52 | Vinchurkar Diagnostics Pvt Ltd | | Narayan Vinchurkar | | Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 6.81 | 0.00 | 0.00 |
| 53 | Vinchurkar Diagnostics Pvt Ltd | | Narayan Vinchurkar | | Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 7.80 | 0.00 | 0.00 |
| 54 | Vinchurkar Diagnostics Pvt Ltd | | Samihan Vinchurkar | | Relative of Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 4.20 | 0.00 | 0.00 |
| 55 | Invicta Medical LLP. | | Dipika Jain | | Relative of Director | Purchase of goods or services | | | Approved by Audit Committee where required | | | 0.04 | 0.00 | 0.00 |
| 56 | Invicta Medical LLP. | | Nikhil Mahatme | | Designated Parter | Purchase of goods or services | | | Approved by Audit Committee where required | | | 4.96 | 0.00 | 0.00 |
| **Total value of transaction during the reporting period** | | | | | | | | | | | | 376.31 | | |

Sanket Vinod Jain

Digitally signed by Sanket Vinod Jain
Date: 2026.11.14 20:19:56 +05'30'